Viewing nowEffient 10 mg Tablet (Prasugrel Hydrochloride)
Prasugrel Hydrochloride 10.98mg
Tablet · Prescription medication
Hanmi Daiichi Sankyo Co., Ltd.

MFDS item code 201004754 · Approved 2010.07.29 · Insurance code 680900220
Prevention of thrombotic cardiovascular events in acute coronary syndrome patients undergoing percutaneous coronary intervention
This medication is used for patients with acute coronary syndrome who have undergone or are to undergo coronary intervention. It is particularly suitable for patients with unstable angina or non-ST elevation myocardial infarction, as well as those with ST elevation myocardial infarction undergoing either primary or delayed coronary intervention. This drug reduces the incidence of thrombotic cardiovascular events, including stent thrombosis. Thrombotic cardiovascular events include death due to cardiovascular disease, non-fatal myocardial infarction, or stroke. Therefore, this medication helps prevent and treat acute cardiovascular problems.
Adults This medicine is for adults weighing 60 kg or more and aged under 75 years (weight ≥ 60 kg, age < 75 years) only. Administer a single oral loading dose of prasugrel 60 milligrams, followed by a maintenance dose of 10 milligrams once daily. However, in patients at high risk of bleeding, administer a maintenance dose of 5 milligrams once daily. (Refer to bleeding risk factors under 1. Warnings and 3. Patients Requiring Caution in the Precautions for Use.) In patients with unstable angina/non-ST-segment elevation myocardial infarction, if coronary angiography is performed within 48 hours after admission, the loading dose must be administered at the time of percutaneous coronary intervention (PCI). Administer this medicine regardless of meals, and use concomitantly with aspirin (75~325 milligrams daily). Patients with renal impairment No dosage adjustment is required for patients with renal impairment; however, use this medicine with caution because experience with its use is limited. Patients with hepatic impairment No dosage adjustment is required for patients with mild to moderate hepatic impairment (Child-Pugh Class A and B); however, use this medicine with caution because experience with its use is limited.
The safety and efficacy of this medicine have not been established in pediatric and adolescent patients aged 18 years or younger.
This medication may cause bleeding; thus, it should not be used in patients with ongoing bleeding or a history of cerebrovascular diseases such as stroke. Elderly patients over 75 years of age or those weighing less than 60 kilograms are at higher risk of bleeding, and use of this medication is not recommended. Patients likely to undergo surgery, such as coronary artery bypass grafting, should discontinue this medication at least 7 days before the surgery. Extra caution should be taken when administered with other medications that may increase the risk of bleeding, and if bleeding symptoms occur, consult a doctor immediately. This medication inhibits platelet aggregation, which can prolong bleeding time. In patients at high risk of bleeding, the decision to administer this medication should be made cautiously, and if bleeding symptoms arise, their condition should be monitored through blood tests. Pregnant or nursing women must consult a healthcare provider before using this medication, and breastfeeding is not recommended during its use. This medication has not been established as safe and effective in children or adolescents under 18 years of age and should not be used in this population. In cases of overdose, the risk of bleeding may increase, so it is essential to adhere to the prescribed dosage and administration. Severe bleeding may require treatment such as platelet transfusion. During the use of this medication, care should be taken when driving or operating machinery, and patients should have regular medical check-ups to reduce the risk of bleeding.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius to safely preserve its efficacy.
Pale yellow hexagonal film-coated tablet
30 tablets (6 tablets/PTPX5)/box
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.